PriceTargets.com logo

Rubius Therapeutics - RUBY Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.06 As of 12/29/2023 01:00 AM ET
+0 (0.00%)
Get New Rubius Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RUBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RUBY

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Rubius Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.06.

This chart shows the closing price for RUBY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Rubius Therapeutics. This rating has held steady since September 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/13/2022GuggenheimDowngradeBuy ➝ Neutral
5/11/2022HC WainwrightLower Target$15.00 ➝ $8.00
4/11/2022Leerink PartnersLower TargetMarket Perform$5.00 ➝ $3.00
4/11/2022Morgan StanleyLower TargetEqual Weight$15.00 ➝ $4.00
4/11/2022GuggenheimLower TargetBuy$25.00 ➝ $5.00
4/11/2022HC WainwrightLower TargetBuy$40.00 ➝ $15.00
2/25/2022Leerink PartnersLower TargetMarket Perform$14.00 ➝ $5.00
1/3/2022GuggenheimLower Target$32.00 ➝ $25.00
12/20/2021Leerink PartnersReiterated RatingHold
11/9/2021Leerink PartnersLower TargetMarket Perform$20.00 ➝ $14.00
8/10/2021HC WainwrightReiterated RatingBuy$40.00
5/18/2021Morgan StanleyBoost TargetEqual Weight$24.00 ➝ $25.00
4/19/2021Morgan StanleyBoost TargetEqual Weight$10.00 ➝ $24.00
3/15/2021HC WainwrightBoost TargetBuy$28.00 ➝ $40.00
3/15/2021Leerink PartnersBoost TargetMarket Perform$4.00 ➝ $20.00
3/1/2021Leerink PartnersLower TargetMarket Perform$5.00 ➝ $4.00
2/23/2021Leerink PartnersReiterated RatingMarket Perform$5.00 ➝ $4.00
1/19/2021Morgan StanleyBoost TargetEqual Weight$5.00 ➝ $10.00
11/11/2020Morgan StanleyBoost TargetEqual Weight$4.00 ➝ $5.00
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutral
8/11/2020HC WainwrightReiterated RatingBuy$28.00
(Data available from 4/23/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/23/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Rubius Therapeutics logo
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts.
Read More

Today's Range

Now: $0.06
Low: $0.06
High: $0.06

50 Day Range

MA: $0.04
Low: $0.02
High: $0.06

52 Week Range

Now: $0.06
Low: $0.00
High: $0.38

Volume

755,858 shs

Average Volume

1,154,788 shs

Market Capitalization

$5.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.59

Frequently Asked Questions

What sell-side analysts currently cover shares of Rubius Therapeutics?

The following sell-side analysts have issued research reports on Rubius Therapeutics in the last twelve months:
View the latest analyst ratings for RUBY.

What is the current price target for Rubius Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Rubius Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Rubius Therapeutics in the next year.
View the latest price targets for RUBY.

What is the current consensus analyst rating for Rubius Therapeutics?

Rubius Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RUBY.

What other companies compete with Rubius Therapeutics?

Other companies that are similar to Rubius Therapeutics include BioAtla, IN8bio, SAB Biotherapeutics, Calidi Biotherapeutics and Curis. Learn More about companies similar to Rubius Therapeutics.

How do I contact Rubius Therapeutics' investor relations team?

Rubius Therapeutics' physical mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company's listed phone number is (508) 543-1720 and its investor relations email address is [email protected]. The official website for Rubius Therapeutics is www.rubiustx.com. Learn More about contacing Rubius Therapeutics investor relations.